“If it appears to a coroner, either before he proceeds to hold an inquest or in the course of an inquest begun without a jury, that there is reason to suspect: (a) (…) (b) (…) (c) (…); or (d) that the death occurred in circumstances, the continuance or possible occurrence of which is prejudicial to the health or safety of the public or any section of the public, he shall proceed to summon a jury in the manner required by subsection (2) above.” (a) (…) (c) (…); or (d) that the death occurred in circumstances, the continuance or possible occurrence of which is prejudicial to the health or safety of the public or any section of the public, he shall proceed to summon a jury in the manner required by subsection (2) above.”
“… Rule 36 should not be interpreted as to defeat the purpose of s.8 (3)(d)… if ‘the proceedings and evidence’ are narrowly confined, the answers to the ‘how’ question will not serve the purpose of the section, the prevention or reduction of the risk of future injuries in similar circumstances.”
“In circumstances where the scope of the inquest is limited to determining “by what means”
“1. The defendant failed to investigate how the deceased came to have a post-mortem concentration of 60 mcg/l Fentanyl in his blood and a post-mortem concentration of 580 mcg/l in his urine... when on the evidence presented to him, the expected range of concentration in Fentanyl in blood after the application of a 100mcg/hr transdermal patch was 1.9 - 3.8 and the average Fentanyl concentrations in 4 adults who died from excessive use of transdermal fentanyl was 23mcg/l (range 12 -- 41) in blood and 233mcg/l (range 89 -- 449) in urine. The defendant did not call expert evidence from a toxicologist. The defendant did not seek appropriate expert evidence from a toxicologist. The defendant did not seek or call evidence from the US manufacturers of Fentanyl or the UK distributors. The defendant did not seek or adduce any appropriate evidence about Fentanyl or its potential complications beyond the expected range of concentration of Fentanyl in blood after the application of a Fentanyl transdermal patch or the expected fatal dose. 2. The defendant did not investigate how the deceased first came to be prescribed Fentanyl transdermal patches in December 2005 or how his prescription came to be increased from 50mcg/hr patches to 100mcg/hr patches. The defendant did not hear evidence from the doctors who prescribed this medication to the deceased. The defendant did not call these witnesses to give evidence. 3. The defendant did not fully investigate how the deceased came to be given a second prescription for 72 hour 100mcg/hr Fentanyl transdermal patches within 24 hours of the first such prescription being collected. ” 4. The defendant did not investigate the beliefs, knowledge and practices of all the individual doctors who prescribed medication to the deceased between23 December 2005 and30 December 2005 , or the contact which the deceased had with NHS Direct during this period fully or at all. 5. The defendant did not investigate any possible system deficiencies related to the policies and procedures of the different health care providers. The defendant did not seek or call any relevant evidence in relation to these issues. 6. The defendant did not investigate the information which was or might have been available to the prescribing doctors or other healthcare care staff with whom the deceased came into contact between23 December 2005 and30 December 2005 about the use of Fentanyl and the potential complications. 7. The defendant did not investigate when the deceased first suffered symptoms of Fentanyl toxicity, what those initial symptoms were, or how the deceased's condition probably deteriorated until he died. The defendant did not call appropriate expert evidence from a toxicologist in relation to these issues.”
“In December 07 there were 36 deaths attributable to fentanyl. As of February 2010 the Medicine and Healthcare Regulatory Agency statistics show that in the last 12 months, there have been 76 fentanyl related deaths. The findings of inquests are vital to understanding the factors that contribute to such a significant increase in fentanyl related deaths. There is a continuing need to alert doctors to the indications for prescribing this drug, its contraindications and drug interactions, side effects and safe prescribing procedures.”